- Home
- NKTR vs TNGX Comparison
NKTR vs TNGX Comparison
Compare NKTR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- TNGX
- Stock Information
- Founded
- NKTR 1990
- TNGX 2014
- Country
- NKTR United States
- TNGX United States
- Employees
- NKTR N/A
- TNGX N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NKTR Health Care
- TNGX Health Care
- Exchange
- NKTR Nasdaq
- TNGX Nasdaq
- Market Cap
- NKTR 1.1B
- TNGX 1.0B
- IPO Year
- NKTR 1994
- TNGX N/A
- Fundamental
- Price
- NKTR $54.35
- TNGX $10.00
- Analyst Decision
- NKTR Strong Buy
- TNGX Strong Buy
- Analyst Count
- NKTR 5
- TNGX 7
- Target Price
- NKTR $89.00
- TNGX $12.00
- AVG Volume (30 Days)
- NKTR 684.3K
- TNGX 3.2M
- Earning Date
- NKTR 11-06-2025
- TNGX 11-04-2025
- Dividend Yield
- NKTR N/A
- TNGX N/A
- EPS Growth
- NKTR N/A
- TNGX N/A
- EPS
- NKTR N/A
- TNGX N/A
- Revenue
- NKTR $62,600,000.00
- TNGX $66,501,000.00
- Revenue This Year
- NKTR N/A
- TNGX $20.41
- Revenue Next Year
- NKTR N/A
- TNGX N/A
- P/E Ratio
- NKTR N/A
- TNGX N/A
- Revenue Growth
- NKTR N/A
- TNGX 53.29
- 52 Week Low
- NKTR $6.48
- TNGX $1.03
- 52 Week High
- NKTR $66.92
- TNGX $10.07
- Technical
- Relative Strength Index (RSI)
- NKTR 44.64
- TNGX 69.47
- Support Level
- NKTR $52.50
- TNGX $7.69
- Resistance Level
- NKTR $61.81
- TNGX $8.35
- Average True Range (ATR)
- NKTR 3.62
- TNGX 0.73
- MACD
- NKTR -0.51
- TNGX 0.16
- Stochastic Oscillator
- NKTR 19.45
- TNGX 97.74
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.